Evolving landscape of HER2-low breast cancer: New diagnosis and treatment paradigm shift

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

Validation of the Labcorp Plasma Focus test to facilitate precision oncology through cell-free DNA genomic profiling of solid tumors

RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers

Population health tools: How lab data can help manage hepatitis C

Hepatitis C (Hep C or HCV) is a significant public health concern in the United States, with an estimated 2.4 million people living with the virus. Approximately 80% of people with hepatitis C have no symptoms and can live for years without knowing they have it. For the remaining 20%, symptoms can include poor appetite, nausea, vomiting and fever. As a result, there is no independent indication for a provider to order hepatitis C testing. Using Labcorp's population health tool, Insight Analytics, providers can generate a list of patients missing confirmatory testing. Providers can then contact individual patients to arrange a confirmatory test and follow-up care. 

Labcorp and BML announce expansion of clinical laboratory testing capabilities in Japan

Advanced technology supports drug development across diseases including cancer and cerebrovascular disease

Labcorp and Providence expand strategic laboratory relationship

Patients and Providers in Oregon Region Will Gain Broader Access to Labcorp's Diagnostic Testing and Laboratory Services Labcorp and Providence Health & Services – Oregon (Providence Oregon) have entered into an agreement for Labcorp to acquire select assets of Providence Oregon's outreach

Algorithmic prediction of response to checkpoint inhibitors

Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient